CND Life Sciences Welcomes 4 New Executives

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, has expanded its leadership team by welcoming four new executives:

• Hernan Lopez joins CND as Chief Operating Officer
• Kathryn Van Wie as Vice President of Strategy & Business Development
• Annemarie Benton as Vice President of Market Access
• Bryan May as Vice President of Information Technology

“We are thrilled to welcome this outstanding group of world-class leaders to the CND executive team,” said Richard J. Morello, CEO of CND Life Sciences. “With their deep breadth of experience in healthcare, medical devices, life science, and biotech, we are well-positioned to expand our work helping physicians and patients detect and treat neurodegenerative diseases easier, safer, and more effectively than ever before.”

Hernan Lopez, COO

As Chief Operating Officer, Hernan Lopez will provide strategic leadership and drive operational excellence across a range of functional areas within CND.

He has nearly 20 years of experience in medical device and life sciences companies. Prior to joining CND, Lopez was the Executive Vice President of Operations at GT Medical Technology, where he brought an innovative medical device for the treatment of brain cancer to market. Prior to GT Medical Technologies, Lopez successfully managed explosive growth venture-backed company operations with successful exits, supported post-merger integrations, and worked in several operations roles in contract manufacturing organizations as well as multinational medical device companies such as Boston Scientific.

Regarding his new appointment, Hernan Lopez remarked, “I am excited to join CND as a true pioneer in the field of neurodegenerative diseases. I look forward to collaborating with CND’s talented and dedicated team to advance our patient mission during this next phase of growth.”

Kathryn Van Wie, VP of Strategy & Business Development

Kathryn Van Wie, Vice President of Strategy & Business Development, will focus on key strategic initiatives including CND’s biomarker capabilities for pharmaceutical clinical trials, international market expansion, and growing partnerships leveraging complementary technologies.

She is an attorney who spent a decade at Vertex Pharmaceuticals as Corporate Counsel and subsequently in US Marketing and as Chief of Staff in Commercial Strategy and Operations.

Annemarie Benton, VP of Market Access

Annemarie Benton, Vice President of Market Access, will oversee the development and execution of CND’s market access and payer engagement strategies.

Benton brings more than 17 years of experience in the life sciences and advanced diagnostic laboratory industries. She began her career as a molecular scientist and leverages her clinical background to advocate for the adoption of precision medicine solutions by navigating the evolving payer landscape. Prior to joining CND, Benton was Head of Managed Care at Bionano and led the payer relations and managed care department at Caris Life Sciences.

Bryan May, VP of Information Technology

Bryan May, Vice President of Information Technology, will be responsible for all IT functions.

With over 25 years of experience across diverse industries including healthcare, distribution, supply chain, and contract manufacturing, May brings a proven track record of driving digital transformation, optimizing IT infrastructure, and implementing solutions to enhance operational efficiency and strategic growth. Prior to joining CND, he worked at Atara Biotherapeutics where he supported infrastructure and cloud services across 3 sites. Before that, he served as the Senior Director of Infrastructure Services and Cloud Engineering at McKesson for 15 years.